Racial and Ethnic Characteristics and Outcomes of Patients Diagnosed with CLL/SLL in the USA.

Autor:	Bruno DS; University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, USA., Khanal M; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA., Li XI; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA., Escalon MP; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA., Winfree KB; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA., Hess LM; Lilly Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA, hess_lisa_m@lilly.com.
Jazyk:	angličtina
Zdroj:	Acta haematologica [Acta Haematol] 2024 May 20, pp. 1-15. Date of Electronic Publication: 2024 May 20.
DOI:	10.1159/000538836
Abstrakt:	Introduction: This study was designed to compare outcomes among patients by race and ethnicity in the post-covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment era. Methods: A nationwide electronic health record (EHR)-derived de-identified database was utilized that included patients diagnosed with CLL from 2013 to 2022 who received systemic therapy for their disease. Use of cBTKi therapy, time to next treatment or death (TTNT-D), and overall survival (OS) were compared by race in unadjusted (Kaplan-Meier method) and adjusted analyses (Cox proportional hazards regression). Results: This study included 4,572 White (71.8%) and 558 Black (8.8%) patients with CLL; 270 were Hispanic or Latino (4.2%). Patients who were Black were significantly younger, more were female, had later stage disease, were of lower socioeconomic status (SES), and were more likely to have unmutated immunoglobulin heavy chain gene (IGHV) and to have received cBTKi therapy than White patients (all p ≤ 0.002). SES was also significantly different by ethnicity. TTNT-D and OS were not different by race in either unadjusted or adjusted analyses (all p > 0.05). Conclusion: In unadjusted and adjusted analyses, TTNT-D and OS were not different by race. These data did not identify racial healthcare disparities in the era following the introduction of cBTKi therapy despite differences in baseline characteristics. (© 2024 The Author(s). Published by S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu